An Insulin-Gold Nanoplatform as Enhanced Antibody-Drug Conjugate Cancer Therapy

The project aims to develop a novel Golden-ADC nanoplatform using insulin-conjugated gold nanoparticles to enhance the efficacy and safety of treatments for triple negative breast cancer.

Subsidie
€ 150.000
2024

Projectdetails

Introduction

Antibody-drug conjugates (ADCs) have emerged as promising therapies by combining the precision targeting abilities of antibodies with the potency of chemotherapy drugs, to directly attack cancer cells and minimize damage to healthy tissue. However, approved ADCs show low efficacies in treating solid tumours, due to inherent challenges.

Challenges in ADCs

These challenges include:

  1. Design Challenges: These limit the drug-antibody ratio and the ability to integrate multiple drug types.
  2. Delivery Challenges: Pharmacokinetics and tumor barriers limit ADC accumulation and distribution within tumours.

Research Framework

In the framework of the ERC-CoG project, we are developing gold nanoparticles (GNPs) that harness insulin for the delivery of large therapeutics, including antibodies, across biological barriers.

Golden-ADC Nanoplatform

As part of this research, we have recently revealed that these insulin-GNPs can be further developed as an ADC nanoplatform.

Features of the Golden-ADC

This Golden-ADC nanoplatform:

  • Enables simple conjugation of large payloads of multiple antibodies and drug types.
  • Shows efficacy in cancer cell models.
  • Enhances in vivo tumor accumulation, together with deep penetration and wide distribution throughout the tumour.

PoC Proposal

In this PoC proposal, we will test our Golden-ADC nanoplatform for effective and safe treatment of triple negative breast cancer.

Importance of the Research

This is due to the potential high benefits that our nanoplatform can provide for this hard-to-treat cancer, which has a long-standing paucity of effective therapies.

Goals of GOLDEN ADC

Within GOLDEN ADC, we aim to achieve significant progress in the technology development process by:

  1. Proof of concept demonstration of efficacy and safety of the Golden-ADC conjugated with multiple drugs in in-vivo triple negative breast cancer models.
  2. Achieving business readiness via:
    • Consolidating the IP strategy.
    • Undertaking a comprehensive market analysis.
    • End-user engagement.
    • Developing the business strategy.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-3-2024
Einddatum31-8-2025
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • BAR ILAN UNIVERSITYpenvoerder

Land(en)

Israel

Vergelijkbare projecten binnen European Research Council

ERC STG

MANUNKIND: Determinants and Dynamics of Collaborative Exploitation

This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.

€ 1.497.749
ERC STG

Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure

The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.

€ 1.498.280
ERC STG

Uncovering the mechanisms of action of an antiviral bacterium

This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.

€ 1.500.000
ERC STG

The Ethics of Loneliness and Sociability

This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.

€ 1.025.860

Vergelijkbare projecten uit andere regelingen

ERC STG

Engineering lipid nanoparticles to target and escape the endosome, deliver their cargo and perform better as breast cancer therapies

This project aims to enhance LNP-mRNA nanomedicine efficacy for advanced breast cancer by improving endosomal escape through nanoscale engineering and tailored formulations.

€ 1.844.248
EIC Pathfinder

Accelerated Discovery Nanobody Platform

The ALADDIN project aims to revolutionize therapeutic antibody discovery for cancer by integrating nanobody technology, AI tools, and innovative models to enhance efficiency and reduce reliance on animal testing.

€ 3.315.441